Plasmid News and Research

RSS

Researchers find a way to turn SARS-CoV-2’s virulence mechanism against itself

A recent study, currently available on the bioRxiv* preprint server, reveals that a specific region of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can be targeted by antisense oligonucleotides to potently inhibit viral replication, and consequently the development of coronavirus disease (COVID-19).

12 Sep 2021

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Researchers in Australia and Finland have provided important insights into how infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – might affect nervous system circuitries and cause neurologic symptoms.

6 Sep 2021

Expansion of seasonal betacoronavirus antibodies post-vaccination is associated with reduction in neutralization of the SARS-CoV-2 variants of concern

A new study determined the antibody response to SARS-CoV-2 and seasonal viruses induced by BNT162b2-Comirnaty vaccination in healthcare workers.

23 Aug 2021

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Researchers in the United States have developed a new model for testing mutations in the four structural proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

9 Aug 2021

Hormone-resistant prostate, breast cancers added to clinical trial of experimental DNA therapy

The Republic of Belarus Ministry of Health has approved expanding the ongoing clinical trial of CureLab Oncology's Elenagen, an experimental DNA therapy, to include two new arms: 1) hormone-resistant breast cancer; and 2) hormone-resistant metastatic prostate cancer.

3 Aug 2021

A quantitative assessment of SARS-CoV-2 bioaerosol production

In an effort to improve the sensitivity and sample recovery of mask sampling, researchers developed a mask sampling tool to assess bioaerosol variation.

28 Jul 2021

Researchers develop a transferrable and integrative type I CRISPR-based platform to edit superbugs

A research team led by Dr Aixin YAN, Associate Professor from the Research Division for Molecular & Cell Biology, Faculty of Science, in collaboration with Honorary Clinical Professor Patrick CY WOO from the Department of Microbiology, Li Ka Shing Faculty of Medicine, the University of Hong Kong, reported the development of a transferrable and integrative type I CRISPR-based platform.

23 Jul 2021

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

A new study published in Vaccine assesses the safety and efficacy of the synthetic DNA vaccine candidate INO-4800, delivered as a single or double dose regime.

18 Jul 2021

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Curia today announced it has entered into a definitive agreement to acquire LakePharma Inc.

From Curia 14 Jul 2021

Use of nanotherapeutics in treating coronavirus diseases

Despite advancements in medicine, viral infections still pose a huge threat to human health and are a significant concern for global public health systems.

22 Jun 2021

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

A new study, released as a preprint on the bioRxiv* server, describes the late-stage clinical trial efficacy of a new vaccine candidate based on a deoxyribonucleic acid (DNA) plasmid platform expressing the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein. Among different constructs of the vaccine plasmid, the RBD was found to produce the most potent and broad immune response.

16 Jun 2021

International travelers often return home with new bacterial strains, confirms study

Carried like stowaways in the guts of international travelers, new and potentially deadly strains of antimicrobial resistant superbugs may be coming to a community near you, suggests new research from Washington University School of Medicine in St. Louis.

7 Jun 2021

Researchers identify kite-shaped molecules that block SARS-CoV-2 cell entry after attachment

They have identified a group of kite-shaped compounds that are highly specific to SARS-CoV-1 and SARS-CoV-2. These compounds demonstrate high potency in inhibiting SARS-CoV-2 infection at early entry steps. The study is currently available on the bioRxiv* preprint server.

2 Jun 2021

Harnessing DNA’s properties to craft “‘topologically tunable” DNA-based materials

While DNA is often idealized as the "molecule of life", it is also a highly sophisticated polymer that can be used for next-generation materials. Beyond the fact that it can store information, further fascinating aspects of DNA are its geometric and topological properties, such as knotting and super-coiling.

31 May 2021

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Researchers in the United States have developed stabilized immunogens presenting the receptor-binding domain (RBD) of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that may improve the scalability of RBD-based coronavirus vaccines.

18 May 2021

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

Preliminary clinical trial results from an ongoing Phase 2/3 trial led by Laurent M. Humeau of Inovio Pharmaceuticals suggest the two-dose INO-4800 vaccine is safe for use in adults of varying ages. The results expand on phase 1 trial results that found the vaccine was safe and tolerable in 38 participants.

16 May 2021

Plasmid News and Research

Researchers find a way to turn SARS-CoV-2’s virulence mechanism against itself

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Expansion of seasonal betacoronavirus antibodies post-vaccination is associated with reduction in neutralization of the SARS-CoV-2 variants of concern

Virus-like particles reveal unexpected mechanism for increased fitness and spread of SARS-CoV-2

Hormone-resistant prostate, breast cancers added to clinical trial of experimental DNA therapy

A quantitative assessment of SARS-CoV-2 bioaerosol production

Researchers develop a transferrable and integrative type I CRISPR-based platform to edit superbugs

Evaluation of a synthetic DNA SARS-CoV-2 vaccine INO-4800 using a nonhuman primate model

Curia to Acquire US-based LakePharma, Expanding End-to-End R&D Capabilities and Scale for Biologics

Use of nanotherapeutics in treating coronavirus diseases

COVID-e-Vax DNA vaccine candidate elicits robust immune responses in preclinical trials

International travelers often return home with new bacterial strains, confirms study

Researchers identify kite-shaped molecules that block SARS-CoV-2 cell entry after attachment

Harnessing DNA’s properties to craft “‘topologically tunable” DNA-based materials

Stabilizing mutations in SARS-CoV-2 immunogens improve vaccine design

Phase 2 trial shows INO-4800 SARS-CoV-2 DNA vaccine safe and tolerable in adults

An intranasal COVID-19 vaccine elicits long-lasting immunity against SARS-CoV-2 variants in vivo

A new strain of common probiotic can potentially be more effective at protecting infant health

New COVID-19 vaccine could provide protection against existing and future strains of coronaviruses

Candidate coronavirus vaccines show promising results in early animal testing

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest Life Science News